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The severe acute respiratory syndrome coronavirus (SARS-CoV)
caused a worldwide epidemic in late 2002/early 2003 and a second
outbreak in the winter of 2003/2004 by an independent animal-
to-human transmission. The GD03 strain, which was isolated from
an index patient of the second outbreak, was reported to resist
neutralization by the human monoclonal antibodies (hmAbs) 80R
and S3.1, which can potently neutralize isolates from the first
outbreak. Here we report that two hmAbs, m396 and S230.15,
potently neutralized GD03 and representative isolates from the
first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16).
These antibodies also protected mice challenged with the Urbani or
recombinant viruses bearing the GD03 and SZ16 spike (S) glycop-
roteins. Both antibodies competed with the SARS-CoV receptor,
ACE2, for binding to the receptor-binding domain (RBD), suggest-
ing a mechanism of neutralization that involves interference with
the SARS-CoV–ACE2 interaction. Two putative hot-spot residues in
the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV
spike that likely contribute to most of the m396-binding energy.
Residues Ile-489 and Tyr-491 are highly conserved within the
SARS-CoV spike, indicating a possible mechanism of the m396
cross-reactivity. Sequence analysis and mutagenesis data show
that m396 might neutralize all zoonotic and epidemic SARS-CoV
isolates with known sequences, except strains derived from bats.
These antibodies exhibit cross-reactivity against isolates from the
two SARS outbreaks and palm civets and could have potential
applications for diagnosis, prophylaxis, and treatment of SARS-
CoV infections.
epitope  paratope  vaccine  therapeutic
The severe acute respiratory syndrome coronavirus (SARS-CoV) (1–4) caused a worldwide epidemic in 2002 and 2003 and
infected8,000 humans with a fatality rate of10%. It reemerged
in the winter of 2003/2004 when four individuals were infected by
an independent transmission from palm civets (5–8). Although
there has not been a natural human outbreak since 2003/2004, the
need to develop potent therapeutics and vaccines against a re-
emerging SARS-CoV remains of high importance because SARS-
CoV or a related virus may be reintroduced into the human
population from an animal reservoir or accidentally released from
a laboratory. SARS-CoV infection leads to generation of potent
neutralizing Abs (nAbs). Antibodies that neutralize the virus in vitro
were also detected in SARS-CoV-infected patients (9–14) and in
mice (15), hamsters (16), and monkeys (17) infected with the virus.
By passive transfer of immune serum before intranasal challenge,
these antibodies also protected naı¨ve animals from SARS-CoV
infection in a mouse model of SARS-CoV replication (15). Several
groups have recently developed human monoclonal Abs (hmAbs)
to the SARS-CoV spike (S) glycoprotein that neutralize the virus
and have potential for therapy and prophylaxis of SARS (18–26; for
review see ref. 23). However, data demonstrating activities of any
of the identified hmAbs against isolates from the second SARS
outbreak and isolates of closely related viruses isolated from
animals have yet to be published. Recently, it was found that the
GD03 strain, isolated from the first patient of the second (2003/
2004) outbreak, is resistant to neutralization by two of the previ-
ously characterized hmAbs, 80R and S3.1 (18–20, 27).
We have previously identified fragments containing the receptor-
binding domain (RBD), which is a major SARS-CoV neutralization
determinant (23, 28–33), and residues critical for its binding to
ACE2 (34, 35). One of these fragments containing residues 317–518
was cloned into a baculovirus expression vector, expressed in insect
cells, and purified. This fragment was used as a selecting antigen for
panning of a large (1010 different antibodies) human antibody Fab
library that we constructed from the B lymphocytes of healthy
volunteers. An antibody, m396, was identified and crystallized in
complex with the RBD, and the structure of the complex was
determined at high (2.3 Å) resolution (36); we also isolated another
antibody, S230.15, from immortalized B cells from a recovered
SARS patient by using a previously developed methodology (18).
An analysis of the structure suggested that m396 could neutralize
isolates from both SARS outbreaks. Here we present evidence that
these antibodies have broadly neutralizing activity against isolates
from the first and second SARS outbreaks as well as from palm
civets in vitro and in an animal model. These antibodies could be
useful for prophylaxis of SARS and treatment of SARS-CoV-
infected patients and as reagents to facilitate development of
therapeutics and vaccines and to help understand their mechanisms
of action.
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Results
Potent in Vitro Inhibition of Entry and Cell Fusion Mediated by the S
Glycoprotein of SARS-CoV Isolates from the 2002/2003 and 2003/2004
Outbreaks and from Palm Civets. We have recently identified an
hmAb, m396, which binds with high affinity to the RBD, and we
determined the crystal structure of the RBDm396 complex at high
resolution (36). A crystal structure analysis suggested that this
antibody could also neutralize the 2003/2004 outbreak isolate
GD03. To test the inhibitory activity of m396 against GD03 and
compare it with that against representative isolates from the first
outbreak, we used viruses pseudotyped with the S glycoprotein of
GD03 and Tor2, an isolate from the 2002/2003 outbreak. IgG1
m396 potently neutralized both GD03 and Tor2 viruses with an IC50
of 0.1 and 0.01 g/ml, respectively (Fig. 1), as well as a virus
pseudotyped with the S glycoprotein from the Urbani isolate (Table
1). M396 also potently neutralized infectious replication-competent
viruses, Urbani and Tor2 isolates, with an IC50 of 0.05 and 0.06
g/ml, respectively (Fig. 2). When tested with another live SARS-
CoV isolate, HKU39849, in Vero E6 cells, 100% inhibition of
infection was achieved at a concentration of 0.6 g/ml. Another
hmAb, S230.15, which we identified by using a methodology based
on EBV transformation of B cells from a convalescent patient (18),
also potently neutralized Urbani and Tor2 isolates (Table 1). Both
antibodies neutralized the pseudotyped viruses bearing spikes from
palm civet isolates SZ3 and SZ16 although with somewhat lower
potency in vitro (Table 1). The neutralizing activity of the antibodies
was similar for virus that infects cells transfected with human or
palm civet ACE2 (data not shown and Table 1). Neither of the two
antibodies caused enhancement of virus entry for any isolate tested
(data not shown and Table 1). The two antibodies also potently
neutralized recombinant replication-competent SARS-CoV iso-
lates Urbani, GD03, and SZ16 (containing the K479N mutation to
facilitate binding to human ACE2) (Table 1). M396 potently
inhibited S-mediated fusion with an IC50 of 0.6 g/ml [supporting
information (SI) Fig. 7A and Table 1]. Under the same experimen-
tal conditions, another SARS-CoV-neutralizing antibody, IgG1
80R (19), exhibited an IC50 of 1.1 g/ml. A control antibody that
potently neutralizes Hendra and Nipah viruses did not show any
inhibitory effect in this assay. These data suggest that both m396
and S230.15 exhibit potent inhibitory activity against isolates from
the 2002/2003 and the 2003/2004 outbreaks as well as against
isolates from palm civets.
Potent Cross-Reactive Inhibitory Activity of m396 and S215.30 in a
Mouse Model of SARS-CoV Infection. We used a mouse model of
SARS-CoV infection to test whether the potent in vitro inhibitory
activity correlated with in vivo protection from infection. Eight-
week-old female BALB/c mice were given m396 at 50 g or 200 g
per mouse, S230.15 at 200 g per mouse, or a control antibody
specific for Hendra and Nipah viruses at 200 g per mouse i.p. 24 h
before challenge with recombinant SARS-CoVs, Urbani, GD03, or
SZ16 (37, 38). Mice that received the control antibody had a mean
titer of Urbani, GD03, or SZ16 virus of 108.1, 106.4, or 107.0 at 50%
infective dose (TCID50) per g of lung tissue, respectively (Fig. 3a).
Mice that received m396 or S230.15 at 200 g per mouse were fully
protected from challenge with Urbani and GD03 viruses; the
protection conferred by m396 from challenge with SZ16 virus was
significant but not complete (Fig. 3a). The protection conferred by
m396 was dose-dependent. The mice receiving 50 g of m396 were
almost completely protected from challenge with SARS-CoV Ur-
bani and less from challenge with GD03 virus. GD03 virus titers in
the lungs of mice that received 50 g of m396 were reduced
1,000-fold compared with titers in mice treated with control
antibody (P  0.009). A similar pattern of dose-dependent inhib-
itory activity against Urbani and GD03 viruses was found in vitro
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Fig. 1. M396 potently neutralizes viruses pseudotyped with S glycoproteins
from the Tor2 and GD03 isolates. HIVs pseudotyped with the S glycoprotein
from Tor2 and GD03 isolates were incubated with IgG1 m396 for 1 h before
infection. Luciferase activities in target cells were measured, and the percent
neutralization was calculated. All experiments were performed in duplicate or
triplicate, and two experiments in different days were performed with essen-
tially identical results. Bars indicate SE.
Table 1. Comparison of the in vitro neutralizing activity of m396
and S215.15 with that of known SARS-CoV-neutralizing hmAbs
Antibody Assay Isolate Activity
m396 Pseudovirus Tor2 0.01
Urbani 1
GD03 0.1
SZ3 1
SZ16 2
Cell fusion Tor2 0.6
Live virus Tor2 0.06
HKU39849 0.6*
Urbani 0.05
Urbani 0.6
GD03 1.7
Recombinant replication-
competent virus
SZ16-K479N 3.4
S230.15 Pseudovirus Urbani 0.07
Tor2 1*
SZ3 1
SZ16 1
Urbani 0.2
GD03 0.3
Recombinant replication-
competent virus
SZ16-K479N 0.2
S3.1 Cytopathicity Urbani 0.3*
Pseudovirus GD03 10
Urbani 1
CR3014 Cytopathicity HKU39849 7*
FM-1 5*
80R Pseudovirus Tor2 2
GD03 50
Syncytia Urbani 4
Cytopathicity Urbani 0.06
Cell fusion Tor2 1.1
201 Cytopathicity Urbani 0.2
scFv B1 Pseudovirus Not reported 4
The data for m396, S230.15, and inhibition of cell fusion by 80R are
described in this work; for S3.1, see refs. 18 and 27; for CR3014, see ref. 21; for
80R, see refs. 19 and 20; for 201, see ref. 24; and for scFv B1, see ref. 22. The
inhibitory activity is represented as IC50 (micrograms/milliliter) except when
followed by *, denoting complete neutralization at the indicated concentra-
tion in micrograms/milliliter.
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(Fig. 1), indicating a correlation between in vitro and in vivo
inhibitory activity.
To find whether the neutralizing activity of the antibodies in
mouse serum correlates with their in vivo inhibitory activity, we also
measured the serum antibody titer by a microneutralization assay.
Indeed, the results showed that high serum-neutralizing titer cor-
responds to better protection reflected by the low levels of virus in
the mouse lungs (compare Fig. 3 a and b). In addition, mice treated
with 200 g of m396 achieved much higher serum-neutralizing
antibody titers to Urbani (1:161 to 1:256) than to GD03 (1:10 to
1:16). The ratio of the two titers (10) is the same as the ratio of
in vitro IC50 values for the two isolates (Fig. 1), indicating that the
antibody retains about the same neutralizing activity in the serum
of animals as in cell culture supernatants. Despite very low levels of
serum-neutralizing antibodies the titer of GD03 in the lungs was
decreased1,000-fold. These results suggest that m396 and S230.15
exhibit potent neutralizing activity against isolates from the 2002/
2003 and 2003/2004 outbreaks and against a palm civet isolate in
vivo that correlates with their neutralizing activity in vitro.
Competition of m396 and S230.15 with the SARS-CoV Receptor ACE2
for Binding to the RBD as a Mechanism of Their Neutralizing Activity.
An analysis of the crystal structure of the RBDm396 complex
predicted that the receptor-binding site on the RBD overlaps the
m396 epitope as shown schematically in Fig. 4, and therefore the
antibody would compete with the receptor for binding to the virus.
To test this prediction and to find the mechanism underlying the
neutralizing activity of m396 and S230.15, we used an ELISA to
measure ACE2 binding to the RBD in the presence of varying
concentrations of the two antibodies. M396 in both formats, Fab
and IgG1, competed with ACE2 (SI Fig. 7B), as predicted from the
crystal structure of the complex. IgG1 was more potent than Fab,
in agreement with its higher effective affinity (avidity) to the
surface-associated RBD as measured previously by surface plas-
mon resonance methodology (36). IgG1 S230.15 also competed
with ACE2 for binding to the RBD although at somewhat higher
concentration (SI Fig. 7B). The Fab m396 competed with S230.15
with about the same activity as with IgG m396, indicating a
significant overlap of the epitopes of these two antibodies (data not
shown). It also competed with mouse monoclonal antibodies that
interfere with the ACE2–RBD interactions (conformational
epitopes groups III, IV, and VI) (30) (data not shown). These
results support the hypothesis that the neutralizing activity of m396
and S230.15 is related to their competition with the receptor ACE2
leading to inhibition of the SARS-CoV interaction with its receptor.
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Fig. 2. Potent neutralization of replication-competent virus by m396. Tor2
and Urbani isolates were incubated with IgG1 m396 for 1 h at 37°C before
infection. After incubation, the percent neutralization was determined by
plaque reduction assay in Vero E6 cells (in duplicate) compared with untreated
controls. Bars indicate SE.
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Fig. 3. Potent neutralization of replication-competent recombinant SARS-CoV
in mice after antibody administration. (a) BALB/c mice, 8 weeks old, were injected
i.p with a control monoclonal antibody at 200 g per mouse; m396 at 50 or 200
g per mouse; or S230.15 at 200g per mouse. Twenty-four hours after antibody
administration, mice were bled to evaluate antibody levels in serum and then
challenged intranasally with 105 TCID50 of the respective recombinant SARS-CoV
(icUrbani, icGD03, or icSZ16-K479N (SZ16). Virus titers in the lung, determined 2
days after challenge, are expressed as log10 TCID50 per g of lung tissue (limit of
detection 101.5 TCID50 per g of lung tissue). (b) Serum-neutralizing antibodies
were measured against specific challenge viruses by microneutralization assays.
The log10-transformed reciprocal dilution at which 50% neutralization occurred
is indicated (limit of detection8 or 100.9). Bars indicate SE.
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Fig. 4. Schematic representation of the SARS-CoV neutralization mecha-
nism. Competition of the antibody (Ab, Fab m396) with the receptor (ACE2)
for binding to the receptor-binding site (RBS) of the RBD of the SARS-CoV S
glycoprotein is shown. The protruding portion of the antibody epitope (in
violet) is also a major portion of the ACE2 receptor-binding site.
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Molecular Mechanisms of the m396 Cross-Reactivity. We used the
high-resolution crystal structure of the RBDm396 complex (36)
and site-directed mutagenesis to analyze the molecular mechanisms
that determine the high-affinity cross-reactive binding of m396.
Guided by the crystal structure, a panel of RBD alanine-scanning
mutants was developed to evaluate the relative contribution of
m396-contacting residues to binding energy. The mutants were
expressed in 293T cells, and their binding to m396 was measured by
ELISA. The level of expression of the mutants was about the same,
which facilitated the interpretation of the binding data (SI Fig. 7C).
Considerable (2-fold or more) reduction in binding was observed
for RBD with mutated residues R395A, R426A, F483A, Y484A,
I489A, Y491A, and Q492A (Fig. 7C). When the residue Tyr-491
was replaced with phenylalanine, the reduction was much smaller
than when it was replaced with glutamine or alanine, suggesting a
role for the benzene ring of the Tyr-491 phenyl group as expected
from the crystal structure. The RBD to m396 binding was not
decreased or was only weakly decreased when the residues Asp-392,
Thr-486, and Thr-487 were mutated to alanine, although according
to the crystal structure they contact the antibody. Similarly, replac-
ing Thr-487 with serine decreased binding only weakly. To test the
possibility that mutations of RBD residues that do not contact
the antibody (noncontact residues) can also affect its binding to the
RBD, e.g., by induced conformational changes, we used another
panel of RBD mutants and found that mutations of Asp-429,
Arg-441, Glu-452, and Asp-454 to alanine also significantly reduced
m396 binding (data not shown).
An analysis of the crystal structure of the RBDm396 complex
showed that amino acid changes in RBDs of GD03, SZ3, and SZ16
from the Tor2 (or Urbani) RBD (in blue in Fig. 5) are different
from the RBD residues that significantly affect binding to m396 as
identified by structure-guided site-directed mutagenesis and de-
scribed above (in red in Fig. 5). Following this approach, we also
analyzed all available sequences of the RBD for SARS-CoV isolates
from humans and palm civets. We found a number of amino acid
residues that differ from those of the RBD sequence for the
prototype Tor2 isolate, which was used in our study to select m396
(Fig. 6). However, none of these residues (except Thr-487, which
affects binding weakly) is in contact with m396 according to the
crystal structure or affects binding indirectly through noncontact
residues (Fig. 6). Thus, mutations of these residues are unlikely to
affect significantly the antibody binding to the RBD, which indicates
that m396 could neutralize all isolates with available sequences,
although some of them with reduced activity (see also Table 1).
Discussion
The major finding of this work is the very high and broad in vitro
and in vivo SARS-CoV-neutralizing activity of the hmAbs m396
and S230.15. Recently, a number of S glycoprotein-specific hmAbs
have been identified, and several of them including S3.1 (18), 80R
(19), CR3014 (21, 26), scFv B1 (22), and 201 (24) have been
extensively characterized. S3.1 prevented the cytopathic effect of
the SARS-CoV at 300 ng/ml (18) and inhibited entry of a pseudovi-
rus with S glycoprotein from Urbani isolate with about the same
IC50 but did not affect entry of a pseudovirus with the GD03 isolate
S glycoprotein and even enhanced the entry of virus pseudotyped
with the S glycoprotein from the palm civet isolate SZ16 (27).
Another antibody, 80R, neutralized 50% of the virus in a micro-
neutralization assay at a concentration as low as 60 ng/ml (19). It
also blocked formation of syncytia, although at significantly higher
concentration (4 g/ml). Its epitope overlaps the binding site of the
SARS-CoV receptor ACE2, suggesting a possible mechanism of
neutralization by preventing the virus attachment to its receptor
(19). This antibody was further tested with a pseudovirus assay; it
inhibited Tor2 isolate with an IC90 of 2 g/ml but had no effect
on the GD03 isolate (20). The neutralizing activity of this antibody
in our cell fusion assay was about 2-fold lower compared with that
of m396 (IC50  1.1 vs. 0.6 g/ml) for the Tor2 isolate. Another
representative antibody, CR3014, protected from the cytopathic
effects of two SARS-CoV isolates, FM1 and HKU39849; the
concentration for protection from HKU39849 was 7 g/ml (21,
26). The scFv B1 neutralized with an IC50 of 4 g/ml in a
pseudovirus assay (22). In a microneutralization assay based on
protection for cytopathic effects, the IC50 for 201 was 0.2 g/ml
Fig. 5. Amino acid residues that are different in GD03 compared with Urbani
(in blue) are located outside the m396 epitope (in red). The antibody contact
residues are shown in red on the surface of the RBD crystal structure deter-
mined in our previous study (36).
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Fig. 6. Analysis of available SARS-CoV sequences and mutagenesis data. M396 is likely to neutralize all isolates with known sequences. Percentage variability
is calculated as the ratio of the number of isolates with a specific mutation to the total number of sequences (72) multiplied by 100. Mutations in SARS-CoV RBD
sequences are shown in blue. Residues critical for binding to m396 are shown in red. The RBD residues that are in contact with both m396 and ACE2 are underlined.
Mutations of noncontact residues that lead to significant decrease of the m396 binding are denoted by an asterisk.
12126  www.pnas.orgcgidoi10.1073pnas.0701000104 Zhu et al.
(24). Our results suggest that both m396 and S230.15 exhibit potent
inhibitory activity against isolates not only from the first outbreak
but also from the second one and from palm civets (Table 1). The
in vitro neutralizing activity of m396 and S230.15 is about the same
or better than that of well characterized SARS-CoV-neutralizing
hmAbs for the isolates tested (Table 1). Importantly, m396 and
S230.15 did not cause enhancement of virus entry for any isolate
tested (data not shown and Table 1) as has been reported for other
antibodies tested by the same in vitro neutralization assay based on
virus pseudotyped with the S glycoproteins of the palm civet isolates
SZ3 and SZ16 (27), and mice that had detectable serum neutral-
izing antibodies had evidence of decreased virus replication in the
lung (Fig. 3). We did not see evidence of enhanced virus replication
in the lungs in the presence of neutralizing antibodies in the serum
that would suggest enhanced disease in the mice.
A major difference between m396 and S230.15, and other hmAbs
tested against the GD03 isolate, is the ability of m396 and S230.15
to cross-neutralize isolates from the two SARS outbreaks. One
should note that we have recently identified mouse monoclonal
antibodies that can also inhibit pseudotyped viruses containing
spikes from both outbreaks (39). The availability of the crystal
structure of m396 in complex with the RBD allowed analysis of the
molecular details of the antibody–RBD interactions. Such analysis
showed that the m396 antibody-combining site is a cleft formed by
its four complementarity determining regions, namely H1, H2, H3,
and L3. The heavy chain alone contributes 65% of the total
antibody-combining site surface area with a high structural comple-
mentarity to its epitope. The crystal structure shows that this deep
pocket could bind to various isolates and accommodate the thre-
onine to serine mutation of residue 487 so it does not significantly
affect the RBD–m396 interaction. Site-directed mutagenesis of
Thr-487 to either alanine or serine did not significantly change the
m396 binding (SI Fig. 7C). This finding implies that in the context
of this residue, m396 would be potent against SARS-CoV isolates
not only from the first outbreak but also from the second one and
against isolates from palm civets, which was confirmed by our data.
An analysis of all known SARS-CoV isolate sequences together
with our mutagenesis data indicate that m396 is likely to neutralize
all of them, although differences in neutralization specificity are
evident among strains. A note of caution is that there is no
guarantee that future isolates will be also sensitive for neutralization
by this antibody. The combination of m395 with S230.15 or other
potent neutralizing antibodies could decrease the probability for
escape mutants with decreased sensitivity to neutralization. Future
experiments especially addressing the possibility for escape mutants
will show the limits of the antibody cross-reactivity.
Most of the currently known hmAbs with potent neutralizing
activity including S3.1, 80R, CR3014, and 201 also significantly
reduced virus load in and/or protected mice or ferrets from
SARS-CoV infection. It was recently found that mAb201 also
exhibits therapeutic efficacy when administered 1 or 2 days after
challenge in a hamster model of SARS-CoV infection (25). Thus,
it was reasonable to expect that m396 and S230.15 would exhibit
similar activity in vivo. Indeed our antibodies prevented or atten-
uated infection of lungs of mice challenged with three different
isolates (Urbani, icGOD3, and icSZ16) at 0.2 mg per mouse.
Taken together, our results demonstrate potential antibody-
based therapeutics against SARS-CoV which could be used alone
or in combination, and they elucidate the molecular mechanisms of
their potent and broad neutralizing activity. These human antibod-
ies could be also used for diagnosis and as research reagents in the
development of vaccines and inhibitors.
Methods
Antibodies. The production of m396 in different formats was
described previously (36). To obtain quantities of IgG1 m396
required for the animal study, we developed a cell line that
expresses the antibody at a relatively high level. The identification,
expression, and purification of S230.15 were done as described
previously (18). The antibody 80R was provided by Wayne Marasco
(Harvard Medical School, Boston, MA). The control antibody
(against Nipah and Hendra viruses) was isolated and produced by
using the same methodology as for m396, which was described
previously (40).
Generation, Expression, and Characterization of RBD Mutants. Point
mutations were generated at specific residues of the RBD using
QuikChange XL site-directed mutagenesis kit (Stratagene,
La Jolla, CA) according to the manufacturer’s directions. The
mutants were expressed and analyzed as described previously (35).
Competition ELISA. Competition among m396, S230.15, and ACE2
for binding to the S protein RBD was measured by using recom-
binant human ACE2 (R&D Systems, Minneapolis, MN) coated in
a coating buffer at 50 ng per well at 4°C overnight, blocked with 3%
nonfat milk in PBS, and washed with PBS/Tween (PBST). C-myc-
tagged RBD (34) at a final concentration of 2 g/ml was incubated
with a serially diluted Fab and IgG1 m396 and a control IgG1
antibody specific for the Hendra virus G protein, respectively, and
the mixtures were then added to ACE2-coated wells in duplicate.
After washing, bound c-myc-tagged RBD was detected by using a
c-myc tag-specific antibody.
Cell Fusion Inhibition Assay. For assessment of the neutralization
activity of the antibodies, a quantitative cell fusion assay based on
-galactosidase (-gal) as a reporter gene was used as described
previously (34). The antibodies were preincubated with 293T cells
transfected with the SARS-CoV S glycoprotein gene at room
temperature for 10 min, then mixed with 293T cells transfected with
ACE2 at 1:1 ratio and incubated at 37°C for 3 h. Cells were then
lysed, and the -gal activity was measured. The antibody concen-
trations during fusion were used for calculation of the IC50 defined
as the concentration at which the-gal activity was reduced by 50%.
Pseudovirus Neutralization Assay. Pseudoviruses containing the S
glycoprotein from various virus isolates, and a defective HIV-1
genome that expresses luciferase as a reporter protein, were
prepared, and the assays performed as described previously
(27, 30, 31).
Infectious Virus Neutralization Assays. Three types of assay
were used: plaque reduction, cytopathicity reduction, and
microneutralization.
Plaque reduction assay. For this assay, all dilutions were made with
Earle’s minimum essential medium with 5% heat-inactivated FBS.
Challenge virus (SARS-CoV Urbani and Tor2) was diluted to a
concentration of 250 pfu/ml, and the antibody preparations ranged
from 1.0 to 0.001 g/ml. The diluted challenge virus was added to
each tube of antibody (0.5 ml) in equal volume with gentle mixing.
The virus/antibody mixtures were incubated in a 37°C water bath for
1 h and subsequently placed on ice. The amount of infectious virus
was quantified by plaque assay in Vero E6 cells. The average
number of plaques for two separate wells per sample was deter-
mined, and the percent plaque reduction was calculated by using
untreated virus as a control. Similar protocol was also used
for testing the antibody inhibitory activity against recombinant
replication-competent viruses. IC50 is defined as the antibody
concentration corresponding to 50% neutralization.
Cytopathicity reduction assay. Serial two-fold dilutions of test antibody
and control antibody were prepared in duplicate, 50 l per well, in
a 96-well tissue culture plate in Earle’s minimum essential medium
and supplemented with 2 mM glutamine/500 g/ml fungizone/100
units/ml penicillin/100 g/ml streptomycin/10% FBS. An equal
volume of SARS-CoV working stock (HKU39849) containing 200
TCID50 was added, and the virus/antibody mixture was incubated
for 30 min at 37°C in a humidified 5% CO2 incubator. Vero E6 cell
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suspension (100-l aliquot) at 2  105 cells/ml was added to wells
of the plate followed by incubation at 37°C in a humidified 5% CO2
incubator. After 3 days, the plate was observed for cytopathic effect.
Neutralization titer was determined from the highest antibody
dilution that produced a 100% inhibition of cytopathic effect in
both wells.
Microneutralization assays for determination of neutralizing antibody
titers. Blood was collected from the tail veins of mice. Serum was
heat-inactivated at 56°C for 30 min and assayed for the presence of
SARS-CoV-neutralizing antibodies. Two-fold dilutions of sera in
L-15 medium (Invitrogen, Carlsbad, CA) were tested in a micro-
neutralization assay for the presence of antibodies that neutralized
the infectivity of 100 TCID50 of recombinant icUrbani, icGD03, or
icSZ16-K479N viruses in Vero cell monolayers as described
previously (15).
Construction of icGD03 and icSZ16-K479N Recombinant Viruses Bear-
ing GD03 and SZ16 K479N S Glycoproteins. Information regarding the
construction and characterization of icGD03 can be found in
Deming et al. (41) and Sheahan et al. (38). The construction and
characterization of icSZ16-K479N (SZ16) were similarly made
except that a K479N mutation was introduced (T.S. and R.B.,
unpublished data). Briefly, the SZ16 spike sequence was inserted
into a molecular clone of SARS Urbani. Residue 479 of the spike
protein was changed from lysine to asparagine to facilitate human
ACE2 binding (42). Recombinant virus was produced as described
previously, plaque-purified, and sequence-verified (37).
SARS-CoV Infection in Mice. All experiments with SARS-CoV,
including animal studies, were conducted in biosafety level 3
facilities, and all personnel wore personal protective equipment
including Tyvek suits and hoods and positive air-purifying respira-
tors. Animal protocols were approved by the Animal Care and Use
Committee of the National Institute of Allergy and Infectious
Diseases/National Institutes of Health. Eight-week-old female
BALB/cAnNTac mice (Taconic, Germantown, NY) were given i.p.
injections of 50 g or 200 g of m396 or 200 g of hmAb S230.15
or 200 g of a control hmAb (0.20 ml total volume, 10 mice per
group). One day after administration of mAbs, mice were bled, and
sera were assayed for SARS-CoV-specific neutralizing antibodies.
After serum collection, mice were lightly anesthetized by isoflurane
(USP–Baxter Healthcare, Deerfield, IL) inhalation and challenged
intranasally with 105 TCID50 of recombinant SARS-CoVs icUrbani
(37), icSZ16-K479N (T.S. and R.B., unpublished data) or icGD03
(41) in 50l total volume. Mice were killed two days after challenge
and lungs were harvested for viral titer determination.
Viral Titer Determination. The lungs were homogenized to a final
10% (wt/vol) suspension in Leibovitz’s L-15 medium (Invitrogen)
with piperacillin (Sigma–Aldrich, St. Louis, MO), gentamicin (In-
vitrogen), and amphotericin B (Quality Biological, Gaithersburg,
MD), which were added to the tissue culture medium at final
concentrations of 0.4 mg/liter, 0.1 mg/liter, and 5 mg/liter, respec-
tively. Lung homogenates were clarified by low-speed centrifuga-
tion and assayed in serial 10-fold dilutions on Vero cell monolayers
as described previously (15). Virus titers are expressed as TCID50
per g of lung with a lower limit of detection of 101.5 TCID50 per g.
Statistical Analyses. The nonparametric Kruskal–Wallis and Mann–
Whitney U statistical methods were used for ascertaining the
significance of observed differences. Statistical significance was
indicated by P values 0.05.
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